{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:01:00Z","timestamp":1794006060745,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Complete Oncologic Resection (COR) for biliary tract cancers (BTC) includes negative margin status and adequate lymphadenectomy, defined as retrieval of \u2265\u20096 lymph nodes. Whether these standards and their association with survival vary across facility types and BTC subtypes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the National Cancer Database (2004\u20132022), we identified adults undergoing curative-intent resection for Stage I-III BTC, excluding T1a gallbladder cancer. Facility types were compared for COR using nested logistic regression, adjusting for demographic and tumor factors. Overall survival (OS) was assessed using multivariable Cox proportional hazards models, with Kaplan-Meier (KM) analyses used to describe unadjusted, stratified survival patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 13,250 adults, 51.6% were treated at academic centers. Negative margins were achieved in 79.5% of academic versus 79.0% elsewhere, while adequate lymphadenectomy occurred in 48.2% versus 38.2%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Non-academic programs had lower odds of COR (OR 0.78\u20130.94), and gallbladder cancer had the lowest odds of each COR component relative to other BTC subtypes (negative margins: OR 0.80, 95% CI 0.69\u20130.93; adequate lymphadenectomy: OR 0.77, 95% CI 0.68\u20130.88). Cox estimates showed higher mortality with positive margins (HR 1.80, 95% CI 1.71\u20131.89), inadequate lymphadenectomy (HR 1.22, 95% CI 1.16\u20131.28), incomplete oncologic surgery (HR 1.36, 95% CI 1.30\u20131.43), and non-academic facilities (HR 1.17, 95% CI 1.12\u20131.23).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Academic centers more frequently deliver COR and are associated with improved survival, but lymphadenectomy benchmarks remain unmet across facility types. System-level interventions, including multidisciplinary collaboration and referral networks, are necessary to expand access to high-quality care and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01421-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:25:16Z","timestamp":1771475116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Facility Type Predicts Completeness of Oncologic Resection and Survival in Biliary Tract Cancers"],"prefix":"10.1007","volume":"57","author":[{"given":"Trisha","family":"Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami O.","family":"Abul-Khoudoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Ammori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Hoehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"10272","key":"1421_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet Lond Engl. 2021;397(10272):428\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7.","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"1421_CR2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/cancers16040684","volume":"16","author":"MH Storandt","year":"2024","unstructured":"Storandt MH, Tella SH, Wieczorek MA, et al. Projected incidence of hepatobiliary cancers and trends based on Age, Race, and gender in the united States. Cancers. 2024;16(4):684. https:\/\/doi.org\/10.3390\/cancers16040684.","journal-title":"Cancers"},{"issue":"2","key":"1421_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2023;34(2):127\u201340. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"1421_CR4","unstructured":"Guidelines Detail. NCCN. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1517.\u00a0Accessed 2 Jun 2025."},{"issue":"4","key":"1421_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1245\/s10434-017-6025-x","volume":"25","author":"YS Chun","year":"2018","unstructured":"Chun YS, Pawlik TM, Vauthey JN. 8th edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845\u20137. https:\/\/doi.org\/10.1245\/s10434-017-6025-x.","journal-title":"Ann Surg Oncol"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jss.2024.09.084","volume":"304","author":"KS Romatoski","year":"2024","unstructured":"Romatoski KS, Chung SH, Sawhney V, et al. Factors associated with surgical management in gallbladder Cancer-A Surveillance, Epidemiology, and end results Medicare-Based study. J Surg Res. 2024;304:9\u201318. https:\/\/doi.org\/10.1016\/j.jss.2024.09.084.","journal-title":"J Surg Res"},{"issue":"7","key":"1421_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the Incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin Status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1. https:\/\/doi.org\/10.1007\/s00268-019-04966-4.","journal-title":"World J Surg"},{"issue":"12","key":"1421_CR8","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1245\/s10434-019-07657-5","volume":"26","author":"GC Lee","year":"2019","unstructured":"Lee GC, Gamblin TC, Fong ZV, et al. Facility type is associated with margin status and overall survival of patients with resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26(12):4091\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07657-5.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1421_CR9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s11605-019-04389-5","volume":"24","author":"A Melillo","year":"2020","unstructured":"Melillo A, Linden K, Spitz F, Atabek U, Gaughan J, Hong YK. Disparities in treatment for gallbladder carcinoma: does treatment site matter? J Gastrointest Surg Off J Soc Surg Aliment Tract. 2020;24(5):1071\u20136. https:\/\/doi.org\/10.1007\/s11605-019-04389-5.","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"2","key":"1421_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jso.25907","volume":"122","author":"C Liu","year":"2020","unstructured":"Liu C, Rein L, Clarke C, et al. Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: an analysis of the National cancer data base. J Surg Oncol. 2020;122(2):176\u201382. https:\/\/doi.org\/10.1002\/jso.25907.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1421_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jso.26924","volume":"126","author":"BJ Kim","year":"2022","unstructured":"Kim BJ, Newhook TE, Tzeng CWD, et al. Lymphadenectomy and margin-negative resection for biliary tract cancer surgery in the united States-Differential technical performance by approach. J Surg Oncol. 2022;126(4):658\u201366. https:\/\/doi.org\/10.1002\/jso.26924.","journal-title":"J Surg Oncol"},{"key":"1421_CR12","unstructured":"National Cancer Database. ACS. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/.\u00a0Accessed 3 Jun 2025."},{"issue":"4","key":"1421_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"1421_CR14","unstructured":"Commission on Cancer. ACS. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/commission-on-cancer\/.\u00a0Accessed 19 Jun 2025."},{"issue":"4","key":"1421_CR15","doi-asserted-by":"publisher","first-page":"e225664","DOI":"10.1001\/jamanetworkopen.2022.5664","volume":"5","author":"BF Bakkila","year":"2022","unstructured":"Bakkila BF, Kerekes D, Nunez-Smith M, et al. Evaluation of Racial disparities in quality of care for patients with Gastrointestinal tract cancer treated with surgery. JAMA Netw Open. 2022;5(4):e225664. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.5664.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1421_CR16","doi-asserted-by":"publisher","first-page":"101961","DOI":"10.1016\/j.gassur.2025.101961","volume":"29","author":"SD Butensky","year":"2025","unstructured":"Butensky SD, Kerekes D, Bakkila BF, et al. Quality of Gastrointestinal surgical oncology care according to insurance status. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2025;29(3):101961. https:\/\/doi.org\/10.1016\/j.gassur.2025.101961.","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"8","key":"1421_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/liv.14856","volume":"41","author":"AM van Keulen","year":"2021","unstructured":"van Keulen AM, Franssen S, van der Geest LG, et al. Nationwide treatment and outcomes of Perihilar cholangiocarcinoma. Liver Int Off J Int Assoc Study Liver. 2021;41(8):1945\u201353. https:\/\/doi.org\/10.1111\/liv.14856.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"4","key":"1421_CR18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1245\/s10434-022-13044-4","volume":"30","author":"Z Moazzam","year":"2023","unstructured":"Moazzam Z, Alaimo L, Endo Y, Lima HA, Pawlik TM. Predictors, Patterns, and impact of adequate lymphadenectomy in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(4):1966\u201377. https:\/\/doi.org\/10.1245\/s10434-022-13044-4.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1421_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","volume":"78","author":"C Sposito","year":"2023","unstructured":"Sposito C, Ratti F, Cucchetti A, et al. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol. 2023;78(2):356\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.021.","journal-title":"J Hepatol"},{"issue":"6","key":"1421_CR20","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1245\/s10434-021-09667-8","volume":"28","author":"PM Kemp Bohan","year":"2021","unstructured":"Kemp Bohan PM, O\u2019Shea AE, Ellis OV, et al. Rates, Predictors, and outcomes of portal lymphadenectomy for resectable gallbladder cancer. Ann Surg Oncol. 2021;28(6):2960\u201372. https:\/\/doi.org\/10.1245\/s10434-021-09667-8.","journal-title":"Ann Surg Oncol"},{"key":"1421_CR21","doi-asserted-by":"publisher","unstructured":"Tripathi M, Vineet K, Joshi N, et al. Conundrum of station 13 lymph nodes in gallbladder carcinoma: retrospective tryst with a forgotten entity. Updat Surg. 2025. https:\/\/doi.org\/10.1007\/s13304-025-02237-7.","DOI":"10.1007\/s13304-025-02237-7"},{"issue":"4","key":"1421_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3748\/wjg.v21.i4.1315","volume":"21","author":"KS Choi","year":"2015","unstructured":"Choi KS, Choi SB, Park P, Kim WB, Choi SY. Clinical characteristics of incidental or unsuspected gallbladder cancers diagnosed during or after cholecystectomy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21(4):1315\u201323. https:\/\/doi.org\/10.3748\/wjg.v21.i4.1315.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1421_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jamcollsurg.2008.02.031","volume":"207","author":"NG Coburn","year":"2008","unstructured":"Coburn NG, Cleary SP, Tan JCC, Law CHL. Surgery for gallbladder cancer: A Population-Based analysis. J Am Coll Surg. 2008;207(3):371\u201382. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.02.031.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"1421_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jso.25825","volume":"121","author":"K Sahara","year":"2020","unstructured":"Sahara K, Tsilimigras DI, Maithel SK, et al. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121(3):503\u201310. https:\/\/doi.org\/10.1002\/jso.25825.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1421_CR25","doi-asserted-by":"publisher","first-page":"e1187","DOI":"10.1097\/SLA.0000000000003788","volume":"274","author":"XF Zhang","year":"2021","unstructured":"Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after Curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2021;274(6):e1187. https:\/\/doi.org\/10.1097\/SLA.0000000000003788.","journal-title":"Ann Surg"},{"issue":"2","key":"1421_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/cncr.34541","volume":"129","author":"KC Ohaegbulam","year":"2023","unstructured":"Ohaegbulam KC, Koethe Y, Fung A, et al. The multidisciplinary management of cholangiocarcinoma. Cancer. 2023;129(2):184\u2013214. https:\/\/doi.org\/10.1002\/cncr.34541.","journal-title":"Cancer"},{"issue":"5","key":"1421_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1159\/000520346","volume":"40","author":"N Ben Khaled","year":"2022","unstructured":"Ben Khaled N, Jacob S, R\u00f6ssler D, et al. Current state of multidisciplinary treatment in cholangiocarcinoma. Dig Dis Basel Switz. 2022;40(5):581\u201395. https:\/\/doi.org\/10.1159\/000520346.","journal-title":"Dig Dis Basel Switz"},{"issue":"12","key":"1421_CR28","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1245\/s10434-016-5343-8","volume":"23","author":"C Meguid","year":"2016","unstructured":"Meguid C, Schulick RD, Schefter TE, et al. The multidisciplinary approach to GI cancer results in change of diagnosis and management of patients. multidisciplinary care impacts diagnosis and management of patients. Ann Surg Oncol. 2016;23(12):3986\u201390. https:\/\/doi.org\/10.1245\/s10434-016-5343-8.","journal-title":"Ann Surg Oncol"},{"key":"1421_CR29","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/OTT.S93629","volume":"10","author":"S Buettner","year":"2017","unstructured":"Buettner S, van Vugt JL, IJzermans JN, Koerkamp BG. Intrahepatic cholangiocarcinoma: current perspectives. OncoTargets Ther. 2017;10:1131\u201342. https:\/\/doi.org\/10.2147\/OTT.S93629.","journal-title":"OncoTargets Ther"},{"issue":"5","key":"1421_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758\u201365. https:\/\/doi.org\/10.1002\/cncr.29824.","journal-title":"Cancer"},{"issue":"3","key":"1421_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.hpb.2018.08.004","volume":"21","author":"A Kommalapati","year":"2019","unstructured":"Kommalapati A, Tella SH, Goyal G, et al. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB. 2019;21(3):379\u201386. https:\/\/doi.org\/10.1016\/j.hpb.2018.08.004.","journal-title":"HPB"},{"issue":"12","key":"1421_CR32","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1634\/theoncologist.2015-0110","volume":"20","author":"M Ambroggi","year":"2015","unstructured":"Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist. 2015;20(12):1378\u201385. https:\/\/doi.org\/10.1634\/theoncologist.2015-0110.","journal-title":"Oncologist"},{"issue":"9","key":"1421_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/OP.22.00122","volume":"18","author":"AN Wercholuk","year":"2022","unstructured":"Wercholuk AN, Parikh AA, Snyder RA. The road less traveled: transportation barriers to cancer care delivery in the rural patient population. JCO Oncol Pract. 2022;18(9):652\u201362. https:\/\/doi.org\/10.1200\/OP.22.00122.","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"1421_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/imj.15039","volume":"51","author":"K Burbury","year":"2021","unstructured":"Burbury K, Wong ZW, Yip D, et al. Telehealth in cancer care: during and beyond the COVID-19 pandemic. Intern Med J. 2021;51(1):125\u201333. https:\/\/doi.org\/10.1111\/imj.15039.","journal-title":"Intern Med J"},{"issue":"16","key":"1421_CR35","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/cncr.32147","volume":"125","author":"BM Bernardo","year":"2019","unstructured":"Bernardo BM, Zhang X, Beverly Hery CM, Meadows RJ, Paskett ED. The efficacy and cost-effectiveness of patient navigation programs across the cancer continuum: A systematic review. Cancer. 2019;125(16):2747\u201361. https:\/\/doi.org\/10.1002\/cncr.32147.","journal-title":"Cancer"},{"issue":"6","key":"1421_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3322\/caac.21788","volume":"73","author":"RJ Chan","year":"2023","unstructured":"Chan RJ, Milch VE, Crawford-Williams F, et al. Patient navigation across the cancer care continuum: an overview of systematic reviews and emerging literature. CA Cancer J Clin. 2023;73(6):565\u201389. https:\/\/doi.org\/10.3322\/caac.21788.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1421_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3322\/caac.20111","volume":"61","author":"ED Paskett","year":"2011","unstructured":"Paskett ED, Harrop JP, Wells KJ. Patient navigation: an update on the state of the science. CA Cancer J Clin. 2011;61(4):237\u201349. https:\/\/doi.org\/10.3322\/caac.20111.","journal-title":"CA Cancer J Clin"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01421-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01421-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:27:51Z","timestamp":1781634471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01421-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01421-1","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}